276 related articles for article (PubMed ID: 10336035)
1. Protection of corneal allografts by CTLA4-Ig.
Gebhardt BM; Hodkin M; Varnell ED; Kaufman HE
Cornea; 1999 May; 18(3):314-20. PubMed ID: 10336035
[TBL] [Abstract][Full Text] [Related]
2. [CTLA4-Ig prevents corneal allograft rejection in mice].
Shi WY; Xie LX
Zhonghua Yan Ke Za Zhi; 2004 Oct; 40(10):696-700. PubMed ID: 16200862
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of corneal allograft reaction by CTLA4-Ig.
Hoffmann F; Zhang EP; Pohl T; Kunzendorf U; Wachtlin J; Bulfone-Paus S
Graefes Arch Clin Exp Ophthalmol; 1997 Aug; 235(8):535-40. PubMed ID: 9285225
[TBL] [Abstract][Full Text] [Related]
4. Effect of administration of CTLA4-Ig as protein or cDNA on corneal allograft survival.
Comer RM; King WJ; Ardjomand N; Theoharis S; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2002 Apr; 43(4):1095-103. PubMed ID: 11923251
[TBL] [Abstract][Full Text] [Related]
5. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism.
Pearson TC; Alexander DZ; Hendrix R; Elwood ET; Linsley PS; Winn KJ; Larsen CP
Transplantation; 1996 Apr; 61(7):997-1004. PubMed ID: 8623206
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.
Shi W; Chen M; Xie L
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1691-7. PubMed ID: 17541621
[TBL] [Abstract][Full Text] [Related]
7. Blockade of the B7-CD28 pathway by CTLA4-Ig counteracts rejection and prolongs survival in small bowel transplantation.
Kurlberg G; Haglind E; Schön K; Törnqvist H; Lycke N
Scand J Immunol; 2000 Mar; 51(3):224-30. PubMed ID: 10736090
[TBL] [Abstract][Full Text] [Related]
8. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates.
Kirk AD; Harlan DM; Armstrong NN; Davis TA; Dong Y; Gray GS; Hong X; Thomas D; Fechner JH; Knechtle SJ
Proc Natl Acad Sci U S A; 1997 Aug; 94(16):8789-94. PubMed ID: 9238056
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
10. Modulation of costimulation by CD28 and CD154 alters the kinetics and cellular characteristics of corneal allograft rejection.
Ardjomand N; McAlister JC; Rogers NJ; Tan PH; George AJ; Larkin DF
Invest Ophthalmol Vis Sci; 2003 Sep; 44(9):3899-905. PubMed ID: 12939307
[TBL] [Abstract][Full Text] [Related]
11. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance.
Zhou P; Szot GL; Guo Z; Kim O; He G; Wang J; Grusby MJ; Newell KA; Thistlethwaite JR; Bluestone JA; Alegre ML
J Immunol; 2000 Nov; 165(10):5580-7. PubMed ID: 11067913
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance.
Steurer W; Nickerson PW; Steele AW; Steiger J; Zheng XX; Strom TB
J Immunol; 1995 Aug; 155(3):1165-74. PubMed ID: 7543517
[TBL] [Abstract][Full Text] [Related]
13. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-Ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice.
Blazar BR; Taylor PA; Linsley PS; Vallera DA
Blood; 1994 Jun; 83(12):3815-25. PubMed ID: 7515723
[TBL] [Abstract][Full Text] [Related]
14. Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion.
Kimura F; Gotoh M; Tanaka T; Luo Z; Miyazaki J; Uede T; Monden M; Miyasaka M
Diabetologia; 2002 Jun; 45(6):831-40. PubMed ID: 12107727
[TBL] [Abstract][Full Text] [Related]
15. Local or short-term systemic costimulatory molecule blockade prolongs rat corneal allograft survival.
Thiel MA; Steiger JU; O'Connell PJ; Lehnert AM; Coster DJ; Williams KA
Clin Exp Ophthalmol; 2005 Apr; 33(2):176-80. PubMed ID: 15807827
[TBL] [Abstract][Full Text] [Related]
16. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
17. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA4-Fc treatment.
Tran HM; Nickerson PW; Restifo AC; Ivis-Woodward MA; Patel A; Allen RD; Strom TB; O'Connell PJ
J Immunol; 1997 Sep; 159(5):2232-9. PubMed ID: 9278311
[TBL] [Abstract][Full Text] [Related]
18. Use of CTLA4-Ig in combination with conventional immunosuppressive agents to prolong allograft survival.
Hale DA; Gottschalk R; Maki T; Monaco AP
Transplantation; 1997 Sep; 64(6):897-900. PubMed ID: 9326417
[TBL] [Abstract][Full Text] [Related]
19. Transplantation tolerance induced by CTLA4-Ig.
Pearson TC; Alexander DZ; Winn KJ; Linsley PS; Lowry RP; Larsen CP
Transplantation; 1994 Jun; 57(12):1701-6. PubMed ID: 8016872
[TBL] [Abstract][Full Text] [Related]
20. Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors.
Li W; Lu L; Wang Z; Wang L; Fung JJ; Thomson AW; Qian S
Transplantation; 2001 Oct; 72(8):1423-32. PubMed ID: 11685115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
